Successful Management of Enzyme Replacement Therapy in Related Fabry Disease Patients with Severe Adverse Events by Switching from Agalsidase Beta (Fabrazyme®) to Agalsidase Alfa (Replagal®)

Tsuboi, Kazuya; Yamamoto, Hiroshi; Fuji, Shigeo; Goto, Hiromi

doi:10.1007/8904_2014_304

JIMD Reports

2014

DOI: 10.1007/8904_2014_304

|View full text |Cite

Successful Management of Enzyme Replacement Therapy in Related Fabry Disease Patients with Severe Adverse Events by Switching from Agalsidase Beta (Fabrazyme®) to Agalsidase Alfa (Replagal®)

Kazuya Tsuboi

Hiroshi Yamamoto

Shigeo Fuji

et al.

Abstract: Background: Enzyme replacement therapy (

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2015

2017

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 28 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent report showed two cases of significant clinical improvement of severe adverse events on an approved/reduced dose of agalsidase beta after the switch to agalsidase alfa. 10 obviously, we need to get further information from all the centers involved in the switch policy.…”

mentioning

confidence: 99%

Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?

Pisani¹,

Riccio²,

Sabbatini³

2015

Genetics in Medicine

View full text Add to dashboard Cite

mentioning

confidence: 99%

Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?

Pisani¹,

Riccio²,

Sabbatini³

2015

Genetics in Medicine

View full text Add to dashboard Cite

Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature

Pisani

Bruzzese

Sabbatini

et al. 2017

Genetics in Medicine

View full text Add to dashboard Cite

The nine studies (217 patients) included in our systematic review showed only marginal differences in most of the evaluated parameters. Seven of these studies were included in the meta-analysis (176 patients). The pooled incidence rate of major adverse events was reported for five studies (150 patients) and was equal to 0.04 events per person-year. No significant change was observed after the shift in glomerular filtration rate, whereas left ventricular mass index, left ventricular posterior wall dimension, and ejection fraction were significantly reduced over time. Our data showed that the switch to agalsidase alfa was well tolerated and associated with stable clinical conditions.Genet Med 19 3, 275-282.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Successful Management of Enzyme Replacement Therapy in Related Fabry Disease Patients with Severe Adverse Events by Switching from Agalsidase Beta (Fabrazyme®) to Agalsidase Alfa (Replagal®)

Abstract: Background: Enzyme replacement therapy (

Cited by 2 publications

References 28 publications

Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?

Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?

Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature

Contact Info

Product

Resources

About